Spotting Red Flags: Understanding how Biotech Top Line Press Releases about FDA Meetings Can "Trick" Investors.
Ticker(s): IBB
A former FDA regulatory official who has worked at the agency and interacted with pharmaceutical companies previously.
This conversation will pull real life examples of press releases and delays to illustrate issues.
Are You Interested In These Questions?
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.